How to Choose a Custom Synthesis Partner: 8 Critical Evaluation Criteria

Why Vendor Selection Matters More Than You Think

The custom synthesis market has expanded dramatically over the past decade. Procurement teams now face hundreds of potential vendors across North America, Europe, India, and China, each claiming world-class capabilities. But the gap between marketing claims and operational reality is often enormous. Industry surveys consistently show that 30-40% of custom synthesis projects experience significant delays, and roughly 15-20% fail to deliver material meeting specifications on the first attempt.

The consequences of a poor vendor choice compound quickly. Consider a pharmaceutical company sourcing a key intermediate for a Phase II clinical trial. A three-month delay in intermediate delivery pushes back API manufacturing by six weeks, which delays formulation by another month, which causes the clinical site to miss its enrollment window. The direct cost of the synthesis may have been $200,000, but the downstream impact of the delay — extended program timelines, additional overhead, opportunity costs — can easily reach $2 million or more.

This is why rigorous vendor evaluation isn’t bureaucratic overhead. It’s risk management.

Criterion 1: Technical Capabilities and Chemistry Expertise

The most fundamental question is whether a potential partner can actually execute the chemistry your project requires. This sounds obvious, but many procurement teams accept vague assurances about “broad synthetic capabilities” without drilling into the specific expertise relevant to their project.

Assessing Reaction Chemistry Competence

Custom synthesis projects span an enormous range of chemical transformations. A vendor with deep expertise in peptide coupling chemistry may have limited experience with organometallic catalysis. A laboratory skilled in heterocyclic synthesis may struggle with large-ring macrocyclization or air-sensitive Grignard reactions. The key is matching your project’s specific chemistry requirements to the vendor’s demonstrated expertise.

During vendor evaluation, request specific examples of projects involving:

• The reaction types central to your synthesis — If your route involves palladium-catalyzed cross-coupling (Suzuki, Heck, Buchwald-Hartwig), ask for case studies demonstrating successful execution of these reactions at the relevant scale. If your target requires asymmetric synthesis using chiral auxiliaries or catalytic enantioselective methods, verify the vendor has delivered compounds with the required enantiomeric excess (typically >99% ee for pharmaceutical applications).

• Handling of challenging functional groups — Molecules containing azides, peroxides, nitro groups, or strained ring systems require specialized safety protocols and equipment. Compounds with multiple sensitive functional groups (e.g., free amines, unprotected aldehydes, or thiol-containing intermediates) demand chemists experienced in orthogonal protecting group strategies.

• Purification expertise — Synthesis is only half the challenge. Many custom synthesis projects fail at the purification stage. Ask about the vendor’s capabilities in chromatographic purification (flash chromatography, preparative HPLC, simulated moving bed chromatography), crystallization development, and distillation. For chiral compounds, determine whether they have access to chiral stationary phases and chiral resolution techniques.

Instrumentation and Equipment Assessment

A vendor’s equipment inventory reveals much about their actual capabilities. Request a current equipment list and evaluate it against your project requirements:

Equipment Category	Minimum Expectation	Advanced Capability
Reactors	Jacketed glass reactors (1-50 L)	Hastelloy or glass-lined steel reactors; high-pressure hydrogenation (up to 100 bar)
Temperature control	-78°C to 150°C range	Cryogenic capabilities (-100°C); high-temperature reactions (>200°C)
Atmosphere control	Nitrogen/argon Schlenk lines	Gloveboxes for air/moisture-sensitive chemistry; ozone generators
Analytical (in-house)	HPLC, NMR (300+ MHz), GC-MS	LC-MS/MS, preparative SFC, HRMS, single-crystal XRD
Purification	Flash chromatography, rotary evaporation	Preparative HPLC, wiped-film distillation, continuous crystallization
Safety	Standard fume hoods, fire suppression	Blast-rated rooms, remote-operation capability for hazardous reactions

A vendor that outsources all analytical testing to a third-party laboratory introduces additional lead time and a point of failure. In-house analytical capabilities — particularly HPLC and NMR — are essential for real-time reaction monitoring and rapid troubleshooting.

Criterion 2: Regulatory Compliance and Certifications

Regulatory compliance requirements vary dramatically depending on your end application. Material destined for a GMP manufacturing campaign has fundamentally different documentation requirements than a research-grade intermediate.

Key Certifications to Verify

• ISO 9001:2015 — The baseline quality management system certification. Any serious custom synthesis vendor should hold current ISO 9001 certification. Request a copy of their certificate and verify it with the issuing registrar.

• cGMP compliance (21 CFR Parts 210/211) — Required if the synthesized material will be used as an active pharmaceutical ingredient or a late-stage intermediate in a drug product. cGMP compliance involves validated processes, qualified equipment, trained personnel, controlled documentation, and regulatory inspection readiness. Not every project requires GMP manufacturing, but if yours does, confirming GMP capability before project initiation is non-negotiable.

• ICH Q7 adherence — The International Council for Harmonisation’s Q7 guideline defines GMP requirements specifically for active pharmaceutical ingredients. A vendor claiming GMP capability should be able to articulate how their operations align with ICH Q7 requirements for process validation, impurity control, change management, and deviation handling.

• DEA registration — If your synthesis involves controlled substance precursors or products (scheduled under the Controlled Substances Act), the vendor must hold appropriate DEA registration. Verify the registration type and schedule coverage.

• EPA and state environmental permits — Chemical manufacturing generates waste streams that require proper permitting. A vendor operating without the correct air emissions, wastewater discharge, and hazardous waste permits is a compliance liability for your organization.

Audit Trail Documentation

Even for non-GMP projects, the quality of a vendor’s documentation reflects their operational discipline. Request examples of their batch records, certificates of analysis, and deviation reports. Well-organized, detailed records indicate a culture of quality. Sparse, inconsistent documentation is a red flag that often correlates with inconsistent product quality.

Criterion 3: Scale-Up Track Record

Many vendors perform well at gram scale but struggle when projects advance to kilogram or multi-kilogram production. Scale-up introduces engineering challenges — heat transfer, mixing efficiency, mass transfer limitations, safety hazards from exothermic reactions — that require process chemistry expertise beyond bench-scale synthetic chemistry.

Questions to Ask About Scale-Up Experience

• What is the largest batch size you have successfully manufactured? Request specific examples with approximate volumes and reactor sizes.
• How do you approach process safety evaluation for scale-up? Look for references to differential scanning calorimetry (DSC) screening, accelerating rate calorimetry (ARC), and reaction calorimetry (RC1e) for thermal hazard assessment.
• Can you provide examples of route modifications you’ve made specifically to enable scale-up? Experienced process chemistry groups routinely replace hazardous reagents (e.g., replacing lithium aluminum hydride with sodium borohydride, or replacing chromium-based oxidants with catalytic TEMPO/bleach systems), eliminate chromatographic purifications in favor of crystallization, and optimize solvent choices for easier recovery and waste management.
• What is your approach to process validation? For GMP work, the vendor should describe a protocol involving installation qualification (IQ), operational qualification (OQ), and process performance qualification (PPQ), consistent with FDA process validation guidance.

The Scale-Up Failure Pattern

A common failure pattern occurs when a vendor accepts a kilogram-scale project based on a milligram-scale route without investing in proper process development. The chemistry that produced 500 milligrams of product in a round-bottom flask may fail catastrophically in a 50-liter reactor due to poor mixing, inadequate temperature control during exothermic additions, or crystallization of intermediates that clogs transfer lines. Experienced scale-up partners budget explicit process development phases before committing to production — and they communicate this honestly during the proposal stage rather than discovering problems after timelines have been committed.

Criterion 4: Intellectual Property Protection

Custom synthesis inherently involves disclosure of proprietary molecular structures, synthetic routes, and sometimes broader program strategies. IP protection should be formalized before any technical discussions begin.

Essential IP Protections

• Confidential Disclosure Agreement (CDA) — Must be executed before sharing any structural or project information. The CDA should specify the scope of confidential information, the duration of protection (typically 5-10 years), permitted uses, and obligations regarding return or destruction of information upon project completion.

• Invention assignment provisions — Your contract should clearly state that any inventions, improvements, or process innovations developed during the project are assigned to your organization, not the vendor. This includes novel synthetic routes, crystalline forms, and purification methods discovered during the work.

• Information security practices — Ask how the vendor stores and transmits confidential information. Electronic laboratory notebooks should have role-based access controls. Project information should be segregated so that personnel working on competitor projects cannot access your data. Physical laboratory notebooks should be stored in locked, access-controlled areas.

• Personnel controls — The vendor should be willing to identify the specific chemists assigned to your project and confirm that those individuals are bound by employment agreements containing non-disclosure and invention assignment provisions.

• Subcontracting restrictions — Your contract should prohibit the vendor from subcontracting any portion of the work without your prior written consent, and require that any approved subcontractor be bound by equivalent confidentiality obligations.

Geographic Considerations for IP

Intellectual property enforcement varies significantly by jurisdiction. Patents and trade secrets receive robust protection in the United States, most EU countries, Japan, and South Korea. Protection in China and India has improved considerably over the past decade but remains less predictable, particularly for smaller companies without the resources for aggressive enforcement. If IP sensitivity is a primary concern, domestic or Western European partners may offer a more favorable risk profile, even at higher per-project cost.

Criterion 5: Quality Systems and Analytical Capabilities

A vendor’s quality system determines whether they can consistently deliver material meeting your specifications — not just on the first batch, but on every subsequent campaign.

Quality System Elements to Evaluate

Quality System Element	What to Look For	Red Flags
Document control	Controlled SOPs with revision history; change control procedures	SOPs stored in personal folders; no version tracking
Deviation management	Formal deviation investigation with root cause analysis (CAPA)	Informal handling; no documentation of deviations
Out-of-specification (OOS) investigation	Written OOS procedure aligned with FDA guidance	Automatic retesting without investigation
Raw material qualification	Incoming material testing or supplier CoA verification	No incoming QC; materials used without identity confirmation
Equipment calibration	Documented calibration schedules; current calibration certificates	Overdue calibrations; no records available
Training records	Documented training for all personnel on relevant SOPs	No training records; verbal-only training
Stability testing	ICH Q1A-compliant stability programs (if applicable)	No stability data available for stored materials

In-House Analytical Versus Outsourced Testing

As noted above, in-house analytical capabilities significantly accelerate project timelines and improve quality oversight. At minimum, a custom synthesis partner should have in-house HPLC (with UV/Vis and ideally mass spectrometric detection), NMR spectroscopy (1H and 13C), and basic physical testing (melting point, Karl Fischer moisture). GC-MS, ICP-MS/OES (for elemental impurity testing per ICH Q3D), and chiral HPLC/SFC are important for projects requiring these analyses. A vendor who must send every sample to an external laboratory for routine characterization will add days or weeks to each project iteration.

Criterion 6: Communication and Project Management

Technical capability is necessary but not sufficient. The operational reality of custom synthesis involves constant communication: route selection decisions, unexpected side reactions, yield shortfalls, analytical anomalies, and timeline adjustments. A vendor’s communication practices determine whether problems are identified and resolved quickly — or whether they fester until the project is critically off-track.

Communication Standards to Establish

• Designated project manager — Every project should have a single point of contact at the vendor who is empowered to make routine decisions and escalate issues appropriately. This individual should have sufficient technical background to discuss chemistry, not just logistics.

• Regular progress reporting — For active synthesis projects, weekly written progress reports should be standard. Reports should include work completed, analytical results obtained, problems encountered, and planned activities for the following week. For longer campaigns, monthly summary reports with milestone tracking provide portfolio-level visibility.

• Proactive problem communication — This is perhaps the single most important communication attribute. Good vendors contact you immediately when they encounter a problem — a reaction that doesn’t work, a yield that falls short, an impurity they can’t remove. Poor vendors stay quiet, hoping to fix the problem before you notice, and contact you only when the timeline is already blown.

• Responsiveness — Establish clear expectations for response times. For active projects, a 24-hour response time for email inquiries and same-day response for urgent issues is reasonable. If a vendor routinely takes 3-5 days to respond to routine questions during the evaluation phase, expect worse performance during active projects.

Evaluating Communication During the Proposal Phase

The proposal process itself is a communication evaluation. Note how long the vendor takes to respond to your RFQ. Assess the technical quality of their proposal — does it demonstrate that they’ve actually analyzed your target molecule and route, or is it a generic template with your compound name inserted? Do they ask clarifying questions that reveal genuine engagement with the technical challenges? A thoughtful, detailed proposal that identifies potential risks and proposes contingency plans is worth far more than a superficial document that promises everything with no caveats.

Criterion 7: Pricing Models and Cost Transparency

Custom synthesis pricing is notoriously opaque. Understanding common pricing models and what drives cost helps procurement teams evaluate proposals on a meaningful basis.

Common Pricing Structures

• Fixed-price (lump sum) — The vendor quotes a single price for delivering the specified quantity at the specified purity. This model transfers cost risk to the vendor, which may be reflected in higher prices (vendors build in contingency) but provides budget certainty. Best suited for well-defined projects where the synthetic route is established and risks are low.

• Time-and-materials (FTE-based) — The vendor charges a daily or monthly rate per chemist (typically $400-$800/day for a bench chemist in the U.S., $250-$500/day in India or China), plus the cost of raw materials and analytical testing. This model is appropriate for early-stage exploratory work where the scope is uncertain, but requires active project management to control costs.

• Milestone-based — The project is divided into defined milestones (e.g., route scouting, process optimization, pilot batch, production batch), each priced separately. Payment is contingent on achieving specified deliverables at each milestone. This hybrid model balances risk between the parties and aligns incentives around progress.

• Cost-plus — The vendor charges actual costs (labor, materials, overhead) plus a defined margin (typically 15-30%). This model provides full cost transparency but offers limited incentive for the vendor to optimize efficiency.

Hidden Costs to Watch For

Beyond the headline price, several cost elements frequently generate surprises:

• Analytical testing charges — Some vendors include routine HPLC and NMR in their synthesis pricing; others bill every analysis separately. Clarify this explicitly.
• Raw material markups — Vendors may purchase starting materials at wholesale prices and mark them up 20-50% before passing costs to you. Request transparency on raw material costs or agree to supply key starting materials directly.
• Shipping and storage — Particularly relevant for temperature-sensitive or hazardous materials. International shipping of chemicals classified under DOT/IATA dangerous goods regulations can add $500-$2,000 per shipment.
• Waste disposal — Large-scale synthesis generates significant waste streams. Some vendors include waste disposal in their overhead; others bill it as a pass-through cost.
• Re-work costs — If a batch fails to meet specifications, who pays for re-synthesis? Establish this contractually before project initiation.

Benchmarking: What Custom Synthesis Should Cost

While pricing varies enormously by molecular complexity, scale, and regulatory requirements, the following ranges provide rough benchmarks for U.S.-based custom synthesis:

Scale	Complexity: Simple (3-5 steps)	Complexity: Moderate (6-10 steps)	Complexity: High (>10 steps or challenging chemistry)
1-10 g	$3,000-$10,000	$8,000-$30,000	$20,000-$75,000
100 g-1 kg	$10,000-$40,000	$30,000-$100,000	$75,000-$300,000
1-10 kg	$30,000-$100,000	$80,000-$250,000	$200,000-$750,000
10-100 kg (GMP)	$100,000-$350,000	$250,000-$800,000	$500,000-$2,000,000+

Proposals significantly below these ranges warrant scrutiny — not celebration. Unrealistically low pricing often indicates that the vendor has underestimated the technical complexity, plans to cut corners on quality, or intends to renegotiate once the project is underway and switching costs are high.

Criterion 8: Track Record and References

Past performance is the best predictor of future results. A vendor’s track record — verified through references, case studies, and audit findings — provides the most reliable indicator of what your experience will be.

Reference Check Protocol

Request a minimum of three client references, ideally from projects similar in scope and complexity to yours. When speaking with references, ask specific questions:

• Did the project deliver on time, or was it delayed? If delayed, by how much and why?
• Did the material meet specifications on the first delivery, or were re-works required?
• How would you characterize the vendor’s communication? Were problems communicated proactively?
• Were there any surprises on pricing — change orders, unexpected charges, or scope disputes?
• Would you use this vendor again for a similar project? Why or why not?
• How did the vendor handle deviations or unexpected technical challenges?

Case Study Evaluation

Request detailed case studies — not marketing summaries, but technical narratives that describe the project challenge, the approach taken, problems encountered, and how they were resolved. A vendor willing to discuss projects where things went wrong (and how they recovered) demonstrates more credibility than one who presents only flawless success stories.

Audit Findings as Quality Indicators

If you have the opportunity to conduct an on-site audit (or review audit reports from other clients or regulatory bodies), pay attention to the nature and severity of findings. No facility is perfect — the question is whether findings reflect minor procedural gaps or systemic quality failures. Repeat findings on the same issue across multiple audits are particularly concerning, as they indicate an inability or unwillingness to implement effective corrective actions.

Building Your Evaluation Scorecard

To apply these eight criteria systematically, consider developing a weighted scorecard that reflects your organization’s priorities. The following weighting is a starting point for pharmaceutical custom synthesis projects:

Criterion	Suggested Weight	Key Evaluation Methods
Technical capabilities	25%	Capability questionnaire, equipment audit, case studies
Regulatory compliance	15%	Certificate verification, audit report review
Scale-up experience	15%	Case studies, reference checks, facility tour
IP protection	10%	CDA review, security assessment, contract terms
Quality systems	15%	On-site audit, document review, OOS investigation records
Communication	5%	Proposal quality, responsiveness during evaluation
Pricing transparency	5%	Proposal detail, benchmarking analysis
Track record	10%	Reference checks, case studies, audit history

Adjust weights according to your specific situation. A discovery-stage project with minimal IP sensitivity might weight technical capability at 35% and IP protection at 5%. A late-stage clinical program requiring GMP material might increase the regulatory compliance and quality systems weights to 20% each.

Red Flags That Should Disqualify a Vendor

Certain findings during evaluation should raise immediate concerns:

• No on-site audit permitted — Any legitimate custom synthesis vendor should welcome a qualified audit. Refusal or persistent delays in scheduling an audit suggest the vendor has something to hide.
• Unable to provide client references — Established vendors have satisfied clients willing to serve as references. A vendor who cannot provide references is either too new to have a track record or has no satisfied clients.
• Pricing dramatically below market — As noted above, unrealistic pricing is a leading indicator of downstream problems.
• No formal quality management system — A vendor operating without documented SOPs, a deviation management process, and a training program is not a vendor — it’s a chemistry laboratory with a purchase order.
• History of regulatory enforcement actions — Check FDA Warning Letters (searchable on the FDA website), EPA enforcement databases, and OSHA violation records. A single minor finding is not necessarily disqualifying, but a pattern of regulatory non-compliance indicates systemic issues.
• High staff turnover — If the experienced chemists who built the vendor’s reputation have departed, the capability you evaluated may no longer exist. Ask about staff retention rates and the tenure of key technical personnel.

The Evaluation Timeline: Plan Ahead

Thorough vendor evaluation takes time. For a new vendor relationship, expect the following timeline:

• Initial screening and RFQ distribution: 2-4 weeks
• Proposal review and shortlisting: 2-3 weeks
• On-site audits of shortlisted vendors: 3-6 weeks (including scheduling, travel, and report preparation)
• Reference checks and due diligence: 2-3 weeks
• Contract negotiation: 2-4 weeks
• Total elapsed time: 3-5 months

This timeline means that vendor qualification should begin well before a synthesis project is urgent. Organizations that wait until material is needed in 8 weeks to begin vendor evaluation end up selecting based on availability rather than capability — and they pay for that shortcut in quality problems, delays, and re-work downstream.